Antimicrobial Susceptibility Testing Market Size, Share & Industry Analysis, By Offering (Instrument and Consumables & Reagents), By Testing Method (Disk Diffusion, Broth Dilution, Agar Dilution, Rapid Phenotypic AST, and Others), By Organism Type (Non-mycobacterial Bacteria, Fungi, and Mycobacteria), By End-user (Hospitals & Hospital-based Laboratories, Independent & Reference Laboratories, Pharmaceutical & Biotechnology Companies, and Others), and Regional Forecast, 2026-2034

The antimicrobial susceptibility testing market size was valued at USD 4.14 billion in 2025 and is projected to grow from USD 4.42 billion in 2026 to USD 7.55 billion by 2034, exhibiting a CAGR of 6.9% during the forecast period. North America dominated the antimicrobial susceptibility testing market with a market share of 34.54% in 2025.

Antimicrobial susceptibility testing (AST) comprises laboratory procedures used to determine whether bacteria, fungi, or other infectious organisms are susceptible, intermediate, or resistant to specific antimicrobial agents. This can be done using disk diffusion method, broth dilution, gradient diffusion, automated phenotypic testing, and others. The growth in implementation of antimicrobial-stewardship programs, national AMR surveillance networks, hospital laboratory automation, and rapid diagnostic pathways is increasing demand for standardized AST instruments, which is anticipated to drive market growth over the forecast period.

BIOMÉRIEUX, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., and Beckman Coulter, Inc. held the highest market share in 2025 due to their diversified product portfolio and focus on increasing investments for novel products.

Antimicrobial Susceptibility Testing Market Key Takeaways

 Global Market Size & Forecast

• 2025 Market Size: USD 4.14 billion
• 2026 Market Size: USD 4.42 billion
• 2034 Forecast Market Size: USD 7.55 billion
• CAGR: 6.9% from 2026–2034

Market Share

• North America dominated the antimicrobial susceptibility testing market with a 34.54% share in 2025.
• Non-mycobacterial bacteria held the largest share by organism type, with an 84.9% share in 2026.
• Hospitals & hospital-based laboratories dominated by end-user, with a 57.6% share in 2026.

Key Regional Highlights

North America

North America led the market with USD 1.43 billion in 2025, supported by established laboratory infrastructure and high AST volumes.

Europe

Europe is projected to reach USD 1.27 billion in 2026 and register a 5.9% CAGR during the forecast period.

Asia Pacific

Asia Pacific is expected to reach approximately USD 1.21 billion in 2026, making it the third-largest regional market.

U.S.

U.S.: The U.S. market is projected to reach USD 1.41 billion in 2026, accounting for approximately 32.0% of global sales.

Japan

Japan: The Japanese market is projected to reach approximately USD 0.29 billion in 2026, representing nearly 6.6% of global sales.

Read More

Antimicrobial Susceptibility Testing Market Trends

Shift Toward Automated, Rapid Phenotypic AST Integrated with Informatics to Emerge as a Key Trend

Currently, there has been a significant shift from isolated manual procedures toward automated platforms combining incubation, Minimum Inhibitory Concentration (MIC) determination, inoculum preparation, quality control, resistance interpretation, and digital reporting. Moreover, rapid phenotypic systems are receiving particular attention as they measure the organism’s actual response to antimicrobial exposure while reducing the time required for therapy optimization.

Furthermore, informatics platforms are simultaneously being integrated with AST instruments to identify unusual resistance patterns, apply expert rules, reduce transcription errors, and communicate urgent results to clinicians. For instance, in April 2025, BD received FDA clearance for integrating the Phoenix M50 and BDXpert systems with the BD Synapsys Informatics Solution.

Market Dynamics

Market Drivers

Download Free sample to learn more about this report.

Rising Prevalence of Antimicrobial Resistance (AMR) and Expansion of AMR Surveillance to Fuel Market Expansion

Over the past few years, there has been an increasing occurrence of multidrug-resistant bacterial infections. This is creating sustained demand for AST across reference laboratories, hospitals, and public-health networks. Additionally, physicians require organism-specific MIC and susceptibility results to increase treatment when resistant pathogens are detected.

Moreover, surveillance programs also depend on standardized AST data to identify emerging resistance, update treatment guidelines, and investigate outbreaks. For instance, the World Health Organization (WHO)’s 2025 global antibiotic-resistance surveillance assessment drew on more than 23.0 million laboratory-confirmed infections reported by 104 countries.

Market Restraints

High Instrument, Consumable and Laboratory Implementation Costs to Hamper Market Growth

Despite growing demand for antimicrobial susceptibility testing, the combined cost of instruments, calibration materials, middleware, proprietary antimicrobial panels, laboratory-information-system connectivity, quality-control strains, service contracts, and personnel training is limited by adoption of advanced AST platforms.

Moreover, laboratories are additionally required to validate new organism-antimicrobial combinations and maintain compliance with changing Clinical and Laboratory Standards Institute (CLSI) or European Committee of Antimicrobial Susceptibility Testing (EUCAST) breakpoints. Such requirements are creating difficulties for small hospitals and laboratories with low specimen volumes. This is expected to hinder market growth during the forecast period.

Market Opportunities

Expansion of Rapid and Point-of-Care AST Solutions to Create Significant Growth Opportunities

Conventional culture-based workflows can delay targeted therapy, particularly for patients with bloodstream infections and sepsis. In response, key players are therefore developing electrical, metabolic, microfluidic, imaging-based, and automated broth-microdilution technologies that shorten time to susceptibility results without abandoning phenotypic measurement.

• For instance, in June 2024, Sysmex Corporation launched the PA-100 AST System in Europe for suspected urinary tract infections, providing bacterial detection in approximately 15 minutes and susceptibility results in as little as 30 minutes.

Furthermore, an expansion into community hospitals, emergency departments, outpatient clinics, and resource-constrained laboratories could significantly broaden the addressable AST customer base, which is expected to contribute to the market’s expansion.

Market Challenges

Maintaining Accuracy Across Evolving Resistance Mechanisms and Breakpoint Updates to Challenge Market Expansion

Ensuring AST systems remain accurate as pathogens acquire new resistance mechanisms and clinical breakpoint recommendations change may pose a significant challenge for the market’s growth over the forecast period. Laboratories and manufacturers need to continuously update antimicrobial menus, databases, software rules, quality-control ranges, and interpretation criteria. The performance of a test also differs by organism, drug, growth medium, inoculum concentration, incubation conditions, and resistance mechanism. This makes the additional claims expensive and time-consuming. Moreover, novel antibiotics require modified testing conditions, but poorly justified deviations from reference methods are expected to produce misleading results. For instance, in August 2025, Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) jointly issued guidance covering the appropriate modification of reference AST methods during antimicrobial development.

Segmentation Analysis

By Offering

Repetitive Purchase of Consumables & Reagents to Fuel Segment’s Growth

Based on offering, the market is segmented into instrument and consumables & reagents.

The consumables & reagents segment accounted for the largest antimicrobial susceptibility testing market share in 2025. Consumables and accessories need recurring purchase based on specimen volume and the number of organism-antimicrobial combinations tested. As a result, key players are increasing their distribution of consumables to meet global demand. This is anticipated to encourage the segment’s growth during the forecast period.

To know how our report can help streamline your business, Speak to Analyst

The instrument segment is projected to grow at a 5.2% CAGR during the forecast period.

By Testing Method

Recognized Usage of Broth Dilution Method to Boost Segment’s Growth

By testing method, the market is segmented into disk diffusion, broth dilution, agar dilution, rapid phenotypic AST, and others.

The broth dilution segment accounted for the largest market share in 2025. Broth microdilution is recognized as a reference methodology for testing rapidly growing aerobic bacteria. It is also widely used to evaluate automated AST systems, new antimicrobial agents, complex resistance patterns, and supports testing of broad antimicrobial menus in standardized multi-well plates. This is expected to favor its utilization, thereby driving the segment growth during the forecast period. Moreover, the segment is estimated to hold a 39.4% share in 2026.

The disk diffusion segment is anticipated to grow at a CAGR of 4.6% over the forecast period.

By Organism Type

Predominant AST Volumes Generated by Gram-Negative and Gram-Positive Pathogens to Drive Nonmycobacterial Bacteria Segment’s Growth

By organism type, the market is classified into non-mycobacterial bacteria, fungi, and mycobacteria.

The non-mycobacterial bacteria segment accounted for the largest market share in 2025. The segment’s growth is attributed to predominant routine AST volumes generated by gram-negative and gram-positive pathogens associated with urinary tract infections, pneumonia, wound infections, bloodstream infections, and healthcare-associated infections. Additionally, increasing burden of urinary tract infections, and others is also contributing to segment’s growth. Moreover, the segment is projected to hold an 84.9% share in 2026.

The fungi segment is expected to grow at a CAGR of 8.3% during the forecast period.

By End-user

High Patient Volume Boosted Hospitals & Hospital-Based Laboratories Segment Growth

On the basis of end-user, the market is segmented into hospitals & hospital-based laboratories, independent & reference laboratories, pharmaceutical & biotechnology companies, and others.

In 2025, hospitals & hospital-based laboratories dominated the market. The segment’s growth is favored by a large number of hospital-based laboratories in developed countries that process large volumes of blood, urine, respiratory, wound, and other clinical specimens from patients requiring immediate antimicrobial treatment. Furthermore, the segment is set to hold a 57.6% market share in 2026.

• For instance, according to the data from Laboratory of Florida LLC, there are 8,680 hospital-based laboratories in the U.S. as of August 2026.

The independent & reference laboratories segment is projected to grow at a CAGR of 8.4% during the forecast period.

Antimicrobial Susceptibility Testing Market Regional Outlook

Based on geography, the market is classified into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America accounted for the largest share in 2024, valued at USD 1.33 billion, and maintained its leading position in 2025, with USD 1.43 billion. The region’s dominance is supported by a well-established laboratory network, standard regulations, and large volumes of AST driven by higher awareness.

• For instance, according to the data published by the Centers for Disease Control and Prevention (CDC) in April 2024, 14.0 billion laboratory tests are performed annually in more than 266,000 Clinical Laboratory Improvement Amendments-certified laboratories in the U.S.

U.S. Antimicrobial Susceptibility Testing Market

In 2026, the U.S. is anticipated to reach USD 1.41 billion, accounting for approximately 32.0% of the global sales.

Europe

Europe is projected to record a CAGR of 5.9% during the forecast period, the second-highest globally. The market is expected to reach USD 1.27 billion in 2026. The region’s growth is due to co-ordinated AMR surveillance infrastructure, standardized laboratory practices, established reimbursement systems, and widespread adoption of automated identification and susceptibility-testing platforms.

U.K. Antimicrobial Susceptibility Testing Market

The U.K. market is projected to reach USD 0.24 billion in 2026, representing approximately 5.3% of global revenues.

Germany Antimicrobial Susceptibility Testing Market

Germany's market is expected to reach USD 0.27 billion in 2026, accounting for approximately 6.1% of global revenues.

Asia Pacific

In 2026, the market in Asia Pacific is projected to reach approximately USD 1.21 billion, making it the third-largest market worldwide. This growth is attributed to a high infectious-disease burden and increasing occurrence of resistant pathogens in the region, which is favoring the need for antimicrobial susceptibility testing.

Japan Antimicrobial Susceptibility Testing Market

Japan is projected to reach approximately USD 0.29 billion in revenue in 2026, representing nearly 6.6% of the global sales.

China Antimicrobial Susceptibility Testing Market

China’s market is anticipated to reach around USD 0.42 billion in 2026, accounting for nearly 9.5% of global revenues.

India Antimicrobial Susceptibility Testing Market

India’s market is expected to reach approximately USD 0.17 billion in 2026, accounting for around 3.8% of global revenues.

Latin America and Middle East & Africa

Latin America and Middle East & Africa are anticipated to witness moderate growth during the forecast period. The Latin America market is estimated to reach approximately USD 0.23 billion in 2026. The antimicrobial susceptibility testing market growth in the region is due to governments’ focus on strengthening national reference laboratories, hospital microbiology capabilities, and regional AMR-reporting systems. The market growth of the Middle East & Africa is mainly due to increasing AMR burden, international laboratory-capacity programs, and national action plans for AST.

GCC Antimicrobial Susceptibility Testing Market

In 2026, the GCC market is estimated to reach approximately USD 0.07 billion, representing around 1.6% of global revenues.

Competitive Landscape

Key Industry Players

Established Global Presence and Key Initiatives by Major Players Boosts their Market Share

In 2025, BIOMÉRIEUX, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., and Beckman Coulter, Inc. held the largest market share. The dominant share of these companies is due to their well-established global presence and widespread distribution network for systems, accessories, and reagents.

Moreover, other key players are focusing on boosting their market share through strategic initiatives such as partnerships, new facility opening, mergers, and acquisitions with other companies to expand product reach.

List of Key Antimicrobial Susceptibility Testing Companies Profiled

• BIOMÉRIEUX (France)
• Thermo Fisher Scientific Inc. (U.S.)
• Beckman Coulter, Inc. (U.S.)
• Bruker (U.S.)
• Q-linea (Sweden)
• QuantaMatrix Inc. (South Korea)
• Sysmex Corporation (Japan)
• Gradientech AB (Sweden)
• Bio-Rad Laboratories, Inc. (U.S.)
• Hardy Diagnostics (U.S.)

Key Industry Developments

• June 2026: Bruker showcased its expanding infection-diagnostics portfolio at ASM Microbe 2026 and outlined a rapid AST workflow under development for bloodstream infections and sepsis.
• April 2026: Q-linea received FDA 510(k) clearance for an expanded ASTar Gram-negative blood-culture testing menu, increasing the number of supported organism-antimicrobial combinations.
• February 2026: Gradientech entered a long-term agreement with ELBLAB GmbH for the clinical use of the QuickMIC ultra-rapid AST system in Germany.
• March 2025: Accelerate Diagnostics submitted the WAVE rapid AST system and its Gram-negative positive-blood-culture menu to the FDA for 510(k) clearance.
• March 2025: BIOMÉRIEUX received FDA clearance for VITEK COMPACT PRO, an automated microorganism-identification and antimicrobial-susceptibility-testing system.
• October 2024: Hardy Diagnostics entered an exclusive partnership to commercialize Gradientech’s QuickMIC ultra-rapid AST system in the U.S. and Canada.
• December 2023: Q-linea installed its first two ASTar systems at U.S. sites ahead of full commercial launch.

Report Coverage

The report provides a detailed analysis of antimicrobial susceptibility testing market across all major segments, highlighting the key growth drivers, trends, opportunities, restraints, and challenges shaping market growth. It also provides technological advancements, recent product launches, market share analysis, key industry developments, and company profiles of major companies operating in the market.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation